Matches in SemOpenAlex for { <https://semopenalex.org/work/W2411530831> ?p ?o ?g. }
Showing items 1 to 84 of
84
with 100 items per page.
- W2411530831 abstract "Background Since 1981, the year of the first case of infection with HIV/AIDS, about 60 million people have been infected with the virus, and some 20 million have died. But since the appearance in 1995 of the so-called highly active antiretroviral therapy, there have been dramatic reductions observed in morbidity and mortality rates. Purpose To evaluate the use of elvitegravir/cobicistat/emtricitabine/tenofovir (EVG/COBI/FTC/TDF) in patients with HIV and to check the adequacy of the prescription, as indicated by the HIV Therapy Group of the regional Pharmacy and Therapeutics Committee in their document ‘Terms of use of EVG/COBI/FTC/TDF’. Material and methods Retrospective observational study in a tertiary hospital. Using the pharmaceutical management software program Savac, the total number of patients receiving EVG/COBI/FTC/TDF from October 2014 to October 2015 (approved use in the hospital) was obtained. The medical record programme Selene provided the following data: age, sex and previous comorbidities. Before initiating a naive or treatment switch with EVG/COBI/FTC/TDF, the use was approved following the guidelines prepared by the HIV Therapy Group. Results 28 patients, 19 (68%) men and 9 (32%) women with a mean age of 49 years, were included in the study. 5 naive patients were identified and the rest were treatment changes. The most common previous treatment schemes were: tenofovir+efavirenz (25%), tenofovir+etravirine (14.3%), tenofovir+darunavir+ritonavir (7%) and lopinavir/ritonavir+tenofovir (7%). The most common comorbidities inducing treatment switch were hepatitis C virus (23%), dyslipidaemia (21%), hypertension (17%), hypercholesterolaemia (7%), adherence problems (3%) and vitamin D deficiency (1%). Conclusion According to the document prepared by the regional HIV Therapy Group, its use is preferable in non-compliant patients, prioritising simplicity to prevent selected resistance. In our study, the most common comorbidity that led to its use as treatment was hepatitis C virus. Starting or changing treatment to EVG/COBI/FTC/TDF complied with the document prepared by the HIV Group in all cases. References and/or Acknowledgements http://www.gesida-seimc.org/contenidos/guiasclinicas/2015/gesida-guiasclinicas-2015-tar.pdf No conflict of interest." @default.
- W2411530831 created "2016-06-24" @default.
- W2411530831 creator A5010663836 @default.
- W2411530831 creator A5013583550 @default.
- W2411530831 creator A5023698125 @default.
- W2411530831 creator A5024879468 @default.
- W2411530831 creator A5032336123 @default.
- W2411530831 creator A5037304064 @default.
- W2411530831 creator A5053124062 @default.
- W2411530831 creator A5063627423 @default.
- W2411530831 creator A5075120894 @default.
- W2411530831 date "2016-02-14" @default.
- W2411530831 modified "2023-09-27" @default.
- W2411530831 title "CP-053 Conditions of use of elvitegravir/cobicistat/emtricitabine/tenofovir in patients with HIV" @default.
- W2411530831 doi "https://doi.org/10.1136/ejhpharm-2016-000875.53" @default.
- W2411530831 hasPublicationYear "2016" @default.
- W2411530831 type Work @default.
- W2411530831 sameAs 2411530831 @default.
- W2411530831 citedByCount "0" @default.
- W2411530831 crossrefType "journal-article" @default.
- W2411530831 hasAuthorship W2411530831A5010663836 @default.
- W2411530831 hasAuthorship W2411530831A5013583550 @default.
- W2411530831 hasAuthorship W2411530831A5023698125 @default.
- W2411530831 hasAuthorship W2411530831A5024879468 @default.
- W2411530831 hasAuthorship W2411530831A5032336123 @default.
- W2411530831 hasAuthorship W2411530831A5037304064 @default.
- W2411530831 hasAuthorship W2411530831A5053124062 @default.
- W2411530831 hasAuthorship W2411530831A5063627423 @default.
- W2411530831 hasAuthorship W2411530831A5075120894 @default.
- W2411530831 hasConcept C126322002 @default.
- W2411530831 hasConcept C142462285 @default.
- W2411530831 hasConcept C159047783 @default.
- W2411530831 hasConcept C2777068322 @default.
- W2411530831 hasConcept C2779182219 @default.
- W2411530831 hasConcept C2779298103 @default.
- W2411530831 hasConcept C2779778239 @default.
- W2411530831 hasConcept C2780404665 @default.
- W2411530831 hasConcept C2780524789 @default.
- W2411530831 hasConcept C2781432083 @default.
- W2411530831 hasConcept C2911190787 @default.
- W2411530831 hasConcept C2993143319 @default.
- W2411530831 hasConcept C3013748606 @default.
- W2411530831 hasConcept C71924100 @default.
- W2411530831 hasConceptScore W2411530831C126322002 @default.
- W2411530831 hasConceptScore W2411530831C142462285 @default.
- W2411530831 hasConceptScore W2411530831C159047783 @default.
- W2411530831 hasConceptScore W2411530831C2777068322 @default.
- W2411530831 hasConceptScore W2411530831C2779182219 @default.
- W2411530831 hasConceptScore W2411530831C2779298103 @default.
- W2411530831 hasConceptScore W2411530831C2779778239 @default.
- W2411530831 hasConceptScore W2411530831C2780404665 @default.
- W2411530831 hasConceptScore W2411530831C2780524789 @default.
- W2411530831 hasConceptScore W2411530831C2781432083 @default.
- W2411530831 hasConceptScore W2411530831C2911190787 @default.
- W2411530831 hasConceptScore W2411530831C2993143319 @default.
- W2411530831 hasConceptScore W2411530831C3013748606 @default.
- W2411530831 hasConceptScore W2411530831C71924100 @default.
- W2411530831 hasLocation W24115308311 @default.
- W2411530831 hasOpenAccess W2411530831 @default.
- W2411530831 hasPrimaryLocation W24115308311 @default.
- W2411530831 hasRelatedWork W1886755341 @default.
- W2411530831 hasRelatedWork W1968543449 @default.
- W2411530831 hasRelatedWork W1994603066 @default.
- W2411530831 hasRelatedWork W1997578665 @default.
- W2411530831 hasRelatedWork W2054544038 @default.
- W2411530831 hasRelatedWork W2151653160 @default.
- W2411530831 hasRelatedWork W2191099001 @default.
- W2411530831 hasRelatedWork W2562313597 @default.
- W2411530831 hasRelatedWork W2626893070 @default.
- W2411530831 hasRelatedWork W2790728876 @default.
- W2411530831 hasRelatedWork W2791565706 @default.
- W2411530831 hasRelatedWork W2800686374 @default.
- W2411530831 hasRelatedWork W2808101981 @default.
- W2411530831 hasRelatedWork W2899831851 @default.
- W2411530831 hasRelatedWork W2948761193 @default.
- W2411530831 hasRelatedWork W2965031403 @default.
- W2411530831 hasRelatedWork W2971007567 @default.
- W2411530831 hasRelatedWork W3016565612 @default.
- W2411530831 hasRelatedWork W3048493976 @default.
- W2411530831 hasRelatedWork W3190984309 @default.
- W2411530831 isParatext "false" @default.
- W2411530831 isRetracted "false" @default.
- W2411530831 magId "2411530831" @default.
- W2411530831 workType "article" @default.